ImmunoGen, Inc. (NASDAQ: IMGN) Q2 2022 earnings call dated Jul. 29, 2022 Corporate Participants: Anabel Chan -- Head of Investor Relations Mark Enyedy -- President &
ImmunoGen Inc.
-(IMGN)
XNAS:IMGN
ImmunoGen, Inc. (IMGN) FY 2021 Earnings Call Transcript
ImmunoGen, Inc. (NASDAQ: IMGN) FY 2021 earnings call dated Feb. 25, 2022 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor
ImmunoGen Inc. (IMGN) Q2 2021 Earnings Call Transcript
ImmunoGen Inc. (NASDAQ: IMGN) Q2 2021 earnings call dated Jul. 30, 2021 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor
ImmunoGen’s post-earnings dip could be a good buying opportunity
Earlier this week, biotech company ImmunoGen (NASDAQ: IMGN) reported mixed financial results for the first quarter of 2021, pushing the stock into
Immunogen, Inc. (IMGN) Q1 2021 Earnings Call Transcript
Immunogen, Inc. (NASDAQ: IMGN) Q1 2021 earnings call dated May. 10, 2021 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor
Earnings calendar for the week of May 10
Stock markets rallied amid mixed cues on the health of the labor market, with latest data showing that payrolls grew at a
Solid pipeline makes ImmunoGen (IMGN) a good long-term investment
ImmunoGen Inc. (NASDAQ: IMGN) last week reported a profit after incurring losses in the first three quarters of last year. The surprise
ImmunoGen Inc. (IMGN) Q4 2020 Earnings Call Transcript
ImmunoGen Inc. (NASDAQ: IMGN) Q4 2020 earnings call dated Feb. 12, 2021 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor
Immunogen Inc (IMGN) Q3 2020 Earnings Call Transcript
Immunogen Inc (NASDAQ: IMGN) Q3 2020 earnings call dated Nov. 06, 2020 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor
Immunogen Inc. (IMGN) Q2 2020 Earnings Call Transcript
Immunogen Inc (NASDAQ: IMGN) Q2 2020 earnings call dated July 31, 2020 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor
ImmunoGen (IMGN) Earnings: 2Q20 Key Numbers
ImmunoGen Inc. (NASDAQ: IMGN) reported second quarter 2020 earnings results today. Revenues were $15 million, compared to $15.5 million in the prior-year period. Net loss
ImmunoGen CEO Mark Enyedy speaks on product strategy, pipeline and more
COVID-19 has been pretty disruptive on clinical-level biotech and pharmaceutical companies worldwide, especially those running on tight budgets. Clinical trials have been
ImmunoGen Inc. (NASDAQ: IMGN) Q1 2020 Earnings Call Transcript
ImmunoGen Inc. (IMGN) Q1 2020 earnings call dated May 01, 2020 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor Relations
Immunogen Inc (NASDAQ:IMGN) Q4 2019 Earnings Call Transcript
Immunogen Inc (IMGN) Q4 2019 earnings call dated Feb 14, 2020 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor Relations Mark
ImmunoGen Inc (IMGN): Q4 2019 Earnings Snapshot
— ImmunoGen Inc. (NASDAQ: IMGN) reported its fourth-quarter 2019 earnings of $0.03 per share vs $0.05 per share loss expected. — Revenue jumped
Immunogen Inc (NASDAQ:IMGN) Q3 2019 Earnings Call Transcript
Immunogen Inc (IMGN) Q3 2019 earnings call dated Nov 1, 2019 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor Relations
Immunogen Inc (NASDAQ: IMGN) Q2 2019 Earnings Call Transcript
Immunogen Inc (IMGN) Q2 2019 earnings call dated Aug 02, 2019 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor Relations Mark
Immunogen Inc (NASDAQ: IMGN) Q1 2019 Earnings Call Transcript
Immunogen Inc (IMGN) Q1 2019 earnings call dated May 03, 2019 Corporate Participants: Sarah Kiely -- Director of Investor Relations Mark Enyedy -- President and Chief Executive Officer
ImmunoGen reports 57% decline in Q1 revenue
ImmunoGen Inc (NASDAQ: IMGN) on Friday reported weaker-than-expected top line in Q1, as the biotech firm continued to burn money on research
ImmunoGen is cheap ahead of Q1 earnings, but is it worth?
ImmunoGen Inc (NASDAQ: IMGN) is one of the worst performing stocks out there, losing about 78% of its value over the course
ImmunoGen reports Q4 loss; stock gains as results beat estimates
Biotechnology firm ImmunoGen Inc. (IMGN) reported a wider net loss for the fourth quarter, hurt by a sharp fall in revenues. However,